These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 17851585)
1. Phase- and stage-related proportions of T cells bearing the transcription factor FOXP3 infiltrate primary melanoma. De Panfilis G; Campanini N; Santini M; Mori G; Tognetti E; Maestri R; Lombardi M; Froio E; Ferrari D; Ricci R J Invest Dermatol; 2008 Mar; 128(3):676-84. PubMed ID: 17851585 [TBL] [Abstract][Full Text] [Related]
2. Utility of tumour-infiltrating CD25+FOXP3+ regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanoma. Miracco C; Mourmouras V; Biagioli M; Rubegni P; Mannucci S; Monciatti I; Cosci E; Tosi P; Luzi P Oncol Rep; 2007 Nov; 18(5):1115-22. PubMed ID: 17914561 [TBL] [Abstract][Full Text] [Related]
3. The vast majority of lymphocytes infiltrating primary cutaneous melanoma express the CD27 costimulatory receptor: implications for melanoma progression. Pepe CA; Ricci R; Cortelazzi C; Mori G; Zambito F; Campanini N; Aimi F; Santoro S; Lombardi M; Santini M; de Panfilis G Eur J Dermatol; 2011; 21(2):178-83. PubMed ID: 21382782 [TBL] [Abstract][Full Text] [Related]
4. Foxp3 expression in melanoma cells as a possible mechanism of resistance to immune destruction. Niu J; Jiang C; Li C; Liu L; Li K; Jian Z; Gao T Cancer Immunol Immunother; 2011 Aug; 60(8):1109-18. PubMed ID: 21547596 [TBL] [Abstract][Full Text] [Related]
5. Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue. Chaput N; Louafi S; Bardier A; Charlotte F; Vaillant JC; Ménégaux F; Rosenzwajg M; Lemoine F; Klatzmann D; Taieb J Gut; 2009 Apr; 58(4):520-9. PubMed ID: 19022917 [TBL] [Abstract][Full Text] [Related]
7. Tumor-reactive CD8+ early effector T cells identified at tumor site in primary and metastatic melanoma. Anichini A; Molla A; Vegetti C; Bersani I; Zappasodi R; Arienti F; Ravagnani F; Maurichi A; Patuzzo R; Santinami M; Pircher H; Di Nicola M; Mortarini R Cancer Res; 2010 Nov; 70(21):8378-87. PubMed ID: 20861189 [TBL] [Abstract][Full Text] [Related]
8. Increased number of CD25 FoxP3 regulatory T cells in oral squamous cell carcinomas detected by chromogenic immunohistochemical double staining. Schwarz S; Butz M; Morsczeck C; Reichert TE; Driemel O J Oral Pathol Med; 2008 Sep; 37(8):485-9. PubMed ID: 18355177 [TBL] [Abstract][Full Text] [Related]
9. Skin melanoma development in ret transgenic mice despite the depletion of CD25+Foxp3+ regulatory T cells in lymphoid organs. Kimpfler S; Sevko A; Ring S; Falk C; Osen W; Frank K; Kato M; Mahnke K; Schadendorf D; Umansky V J Immunol; 2009 Nov; 183(10):6330-7. PubMed ID: 19841169 [TBL] [Abstract][Full Text] [Related]
10. Absence of amplification of CD4+CD25(high) regulatory T cells during in vitro expansion of tumor-infiltrating lymphocytes in melanoma patients. Knol AC; Lemaître F; Pandolfino MC; Volteau C; Quéreux G; Saiagh S; Khammari A; Viguier M; Dréno B Exp Dermatol; 2008 May; 17(5):436-45. PubMed ID: 18312383 [TBL] [Abstract][Full Text] [Related]
11. [Impact of СD8/FoxP3 T lymphocyte ratio in the peritumoral area of primary cutaneous melanoma on the prognosis of the disease]. Bozhchenko YA; Vishnevskaya YV; Pokataev IA; Kokosadze NV; Demidov LV Arkh Patol; 2016; 78(4):27-31. PubMed ID: 27600779 [TBL] [Abstract][Full Text] [Related]
12. TGF-beta1 modulates Foxp3 expression and regulatory activity in distinct CD4+ T cell subsets. Pyzik M; Piccirillo CA J Leukoc Biol; 2007 Aug; 82(2):335-46. PubMed ID: 17475784 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of tumour-infiltrating CD4+CD25+FOXP3+ regulatory T cells in human cutaneous benign and atypical naevi, melanomas and melanoma metastases. Mourmouras V; Fimiani M; Rubegni P; Epistolato MC; Malagnino V; Cardone C; Cosci E; Nisi MC; Miracco C Br J Dermatol; 2007 Sep; 157(3):531-9. PubMed ID: 17596146 [TBL] [Abstract][Full Text] [Related]
14. The microenvironment in primary cutaneous melanoma with associated spontaneous tumor regression: evaluation for T-regulatory cells and the presence of an immunosuppressive microenvironment. Gray A; Grushchak S; Mudaliar K; Kliethermes S; Carey K; Hutchens KA Melanoma Res; 2017 Apr; 27(2):104-109. PubMed ID: 28125447 [TBL] [Abstract][Full Text] [Related]
15. Immunophenotypic Differences in Tumor-Infiltrating Lymphocytes and Neovascularization Between Primary Cutaneous Melanoma With and Without Metastasis: An Immunohistochemical Study of 80 Cases. Salgüero I; Roustán G; Requena L; Suárez D; García-Fresnadillo D; Redondo JI; Nájera L Am J Dermatopathol; 2021 Nov; 43(11):811-818. PubMed ID: 33534211 [TBL] [Abstract][Full Text] [Related]
16. Melanoma induces immunosuppression by up-regulating FOXP3(+) regulatory T cells. Baumgartner J; Wilson C; Palmer B; Richter D; Banerjee A; McCarter M J Surg Res; 2007 Jul; 141(1):72-7. PubMed ID: 17574040 [TBL] [Abstract][Full Text] [Related]
17. FOXP3+ T regulatory lymphocytes in primary melanoma are associated with BRAF mutation but not with response to BRAF inhibitor. Leslie C; Bowyer SE; White A; Grieu-Iacopetta F; Trevenen M; Iacopetta B; Amanuel B; Millward M Pathology; 2015 Oct; 47(6):557-63. PubMed ID: 26308130 [TBL] [Abstract][Full Text] [Related]
18. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer. Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453 [TBL] [Abstract][Full Text] [Related]
19. Increased regulatory T-cell frequencies in patients with advanced melanoma correlate with a generally impaired T-cell responsiveness and are restored after dendritic cell-based vaccination. Correll A; Tuettenberg A; Becker C; Jonuleit H Exp Dermatol; 2010 Aug; 19(8):e213-21. PubMed ID: 20500773 [TBL] [Abstract][Full Text] [Related]
20. Prognostic value of tumor-infiltrating Foxp3+ T-cell subpopulations in metastatic melanoma. Knol AC; Nguyen JM; Quéreux G; Brocard A; Khammari A; Dréno B Exp Dermatol; 2011 May; 20(5):430-4. PubMed ID: 21410773 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]